Literature DB >> 21232803

Giant cell arteritis: laboratory predictors of a positive temporal artery biopsy.

Matthew D Walvick1, Michael P Walvick.   

Abstract

PURPOSE: To identify laboratory predictors of a positive temporal artery biopsy.
DESIGN: Cross-sectional study using retrospective electronic data base review. PARTICIPANTS: There were 3001 patients who had a temporal artery biopsy.
METHODS: The electronic database of a large health maintenance organization was searched for all patients who had a temporal artery biopsy performed from 1997 to 2006. MAIN OUTCOME MEASURES: Odds ratios for erythrocyte sedimentation rate, C-reactive protein (CRP), and platelet count values associated with a positive temporal artery biopsy.
RESULTS: Four hundred fifty-nine cases of biopsy-proven giant cell arteritis were identified. The odds of a positive biopsy were 1.5 times greater with an erythrocyte sedimentation rate of 47 to 107 mm/hr, 5.3 times greater with a CRP >2.45 mg/dL, and 4.2 times greater with platelets >400,000/μL.
CONCLUSIONS: In this largest population-based giant cell arteritis study in the United States to date, we reaffirm Hayreh's finding of the significance of a CRP level >2.45 mg/dL in predicting a positive biopsy. Our findings support the literature suggesting that CRP and thrombocytosis may be stronger predictors of positive biopsy than erythrocyte sedimentation rate. FINANCIAL DISCLOSURE(S): The authors have no proprietary or commercial interest in any of the materials discussed in this article.
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21232803     DOI: 10.1016/j.ophtha.2010.10.002

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  23 in total

Review 1.  Recent advances in diagnostic strategies for giant cell arteritis.

Authors:  Tanaz A Kermani; Kenneth J Warrington
Journal:  Curr Neurol Neurosci Rep       Date:  2012-04       Impact factor: 5.081

2.  Comment on: How common is inflammatory marker-negative disease in giant cell arteritis?

Authors:  T A Kermani; K J Warrington
Journal:  Eye (Lond)       Date:  2013-03-08       Impact factor: 3.775

3.  Response to comment on: how common is inflammatory marker-negative disease in giant cell arteritis?

Authors:  S L Levy; A D Bull; A R Nestel
Journal:  Eye (Lond)       Date:  2013-03-08       Impact factor: 3.775

4.  Baseline clinical predictors of an ultimate giant cell arteritis diagnosis in patients referred to temporal artery biopsy.

Authors:  Chagai Grossman; Iris Barshack; Nira Koren-Morag; Ilan Ben-Zvi; Gil Bornstein
Journal:  Clin Rheumatol       Date:  2016-03-01       Impact factor: 2.980

Review 5.  Facial nerve injury during temporal artery biopsy.

Authors:  A R Gunawardene; H Chant
Journal:  Ann R Coll Surg Engl       Date:  2014-05       Impact factor: 1.891

Review 6.  Giant cell arteritis: ophthalmic manifestations of a systemic disease.

Authors:  Elisabeth De Smit; Eoin O'Sullivan; David A Mackey; Alex W Hewitt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-05       Impact factor: 3.117

7.  Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis.

Authors:  Tanaz A Kermani; Jean Schmidt; Cynthia S Crowson; Steven R Ytterberg; Gene G Hunder; Eric L Matteson; Kenneth J Warrington
Journal:  Semin Arthritis Rheum       Date:  2011-11-25       Impact factor: 5.532

8.  Morphological features of temporal arteritis.

Authors:  William C Roberts; Saleha Zafar; Jo Mi Ko
Journal:  Proc (Bayl Univ Med Cent)       Date:  2013-04

9.  Temporal arteritis.

Authors:  Andrew W Lee; Celia Chen; Sudha Cugati
Journal:  Neurol Clin Pract       Date:  2014-04

10.  Predictive value of positive temporal artery biopsies in patients with clinically suspected giant cell arteritis considering temporal artery ultrasound findings.

Authors:  Falk Sommer; Eberhard Spörl; Robert Herber; Lutz E Pillunat; Naim Terai
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-08-15       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.